- Home
- CLLS vs LUNG Comparison
CLLS vs LUNG Comparison
Compare CLLS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- LUNG
- Stock Information
- Founded
- CLLS 1999
- LUNG 1995
- Country
- CLLS France
- LUNG United States
- Employees
- CLLS N/A
- LUNG N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- CLLS Health Care
- LUNG Health Care
- Exchange
- CLLS Nasdaq
- LUNG Nasdaq
- Market Cap
- CLLS 240.2M
- LUNG 248.0M
- IPO Year
- CLLS 2007
- LUNG 2020
- Fundamental
- Price
- CLLS $1.99
- LUNG $6.82
- Analyst Decision
- CLLS Buy
- LUNG Strong Buy
- Analyst Count
- CLLS 2
- LUNG 7
- Target Price
- CLLS $8.00
- LUNG $13.71
- AVG Volume (30 Days)
- CLLS 23.2K
- LUNG 217.5K
- Earning Date
- CLLS 11-04-2024
- LUNG 10-28-2024
- Dividend Yield
- CLLS N/A
- LUNG N/A
- EPS Growth
- CLLS N/A
- LUNG N/A
- EPS
- CLLS N/A
- LUNG N/A
- Revenue
- CLLS $19,635,000.00
- LUNG $76,583,000.00
- Revenue This Year
- CLLS $271.02
- LUNG $22.73
- Revenue Next Year
- CLLS $33.48
- LUNG $19.02
- P/E Ratio
- CLLS N/A
- LUNG N/A
- Revenue Growth
- CLLS N/A
- LUNG 26.26
- 52 Week Low
- CLLS $0.96
- LUNG $5.46
- 52 Week High
- CLLS $3.77
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- CLLS 42.28
- LUNG 37.18
- Support Level
- CLLS $1.88
- LUNG $6.56
- Resistance Level
- CLLS $2.07
- LUNG $7.47
- Average True Range (ATR)
- CLLS 0.10
- LUNG 0.37
- MACD
- CLLS -0.02
- LUNG -0.21
- Stochastic Oscillator
- CLLS 31.94
- LUNG 11.93
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.